Please provide your email address to receive an email when new articles are posted on . More frequent HCV testing was cost-effective among people who inject drugs in both high- and low-transmission ...
Hosted on MSN
New weekly injectable drug could transform the lives of people living with Parkinson’s disease
A new weekly injection may soon transform how millions manage Parkinson’s disease. For over 8.5 million people living with this condition worldwide, daily treatment has meant taking levodopa and ...
People who inject drugs are dying at an alarming rate from endocarditis, a serious but treatable heart-valve infection. But their odds of survival improve dramatically, even five years after their ...
Please provide your email address to receive an email when new articles are posted on . Measurements taken for HCV cure at 4 weeks produced identical results for people who inject drugs as those taken ...
Patients with cancer, autoimmune diseases, and metabolic disorders often endure hours-long intravenous infusions. These treatments involve protein-based drugs, which must be given in high doses but ...
UW drug use survey shows drop in injection use, sparks debate over housing-first approach in Seattle
A new University of Washington (UW) survey is raising new questions about drug use trends in the region, showing a sharp ...
Cosentyx (secukinumab) comes as a subcutaneous injection under the skin or an intravenous (IV) infusion into a vein. Doctors may prescribe it to treat plaque psoriasis, psoriatic arthritis, and other ...
You can inject Repatha (evolocumab) at any time of day that’s convenient for you. The manufacturer doesn’t recommend a best time of day to inject Repatha. The time you choose won’t alter the drug’s ...
Results from the latest Syringe Services Program (SSP) Health Survey reveal that, since 2021, there has been a 49 percentage ...
GLP-1 agonists have become the dominant spend catalyst, with class spending ~$132B and growth contribution approaching ...
Tennessee hospitalizations for injection drug use-related infections remain a major clinical and economic burden despite rates plateauing after 2018.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results